Gilead HCV Sales Decline In US, But Offset By Global Growth
This article was originally published in Scrip
Executive Summary
Strong sales growth continues almost unabated at Gilead Sciences Inc., but the virology powerhouse reported that domestic sales for its hepatitis C drugs actually decreased by 26% year-over-year during the fourth quarter.
You may also be interested in...
Gilead Not Bullet-Proof After All: Harvoni US Sales Tumble More Than 50%
Incoming President and CEO John Milligan opened Gilead Sciences Inc.'s first quarter earnings call April 28 talking about sales growth of new HIV drugs and pipeline efforts in non-alcoholic steatohepatitis (NASH), but analysts focused in quickly on overall reductions in hepatitis C sales, including a more than 50% decrease year-over-year in US sales of Harvoni.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.